Drug Type Small molecule drug |
Synonyms D07001-Softgel, Gemcitabine, Gemcitabine (USAN/INN) + [4] |
Target |
Action inhibitors |
Mechanism RNR inhibitors(Ribonucleotide reductase inhibitors), DNA synthesis inhibitors |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date- |
RegulationOrphan Drug (United States) |
Molecular FormulaC9H11F2N3O4 |
InChIKeySDUQYLNIPVEERB-QPPQHZFASA-N |
CAS Registry95058-81-4 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02368 | Gemcitabine |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Cancer | Phase 3 | - | 01 Jun 2023 | |
Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 | Australia | 04 Aug 2022 | |
Locally Advanced Pancreatic Adenocarcinoma | Phase 3 | United States | 12 Mar 2018 | |
Locally Advanced Pancreatic Adenocarcinoma | Phase 3 | Belgium | 12 Mar 2018 | |
Advanced Lung Squamous Cell Carcinoma | Phase 3 | United States | 01 Mar 2010 | |
Advanced Lung Squamous Cell Carcinoma | Phase 3 | Belgium | 01 Mar 2010 | |
Advanced Lung Squamous Cell Carcinoma | Phase 3 | Canada | 01 Mar 2010 | |
Advanced Lung Squamous Cell Carcinoma | Phase 3 | France | 01 Mar 2010 | |
Advanced Lung Squamous Cell Carcinoma | Phase 3 | Germany | 01 Mar 2010 | |
Advanced Lung Squamous Cell Carcinoma | Phase 3 | Hungary | 01 Mar 2010 |
Not Applicable | Advanced biliary tract cancer First line | 45 | eahtznikrn(ivchebbhlx) = zrexwaqrra bgdtaiqgyu (dpmgxqmafp ) View more | Positive | 30 May 2025 | ||
Phase 2/3 | 89 | (Chemotherapy (Cisplatin-Gemcitabine)) | lnovudxrox(rxohcmbjzp) = vdfufeesrk toksziexpa (xtiesisvgg, octngondhv - ranbxpoxvs) View more | - | 09 May 2025 | ||
(Radiation: SIRT + Chemotherapy (Cisplatin-Gemcitabine)) | lnovudxrox(rxohcmbjzp) = ostbdvisia toksziexpa (xtiesisvgg, vvzexagkag - qnoplqsvwa) View more | ||||||
Phase 2 | 82 | xtjsqlfxpw = xmgfashegg cbvlpbbojs (mervxwggkt, sxmfpwrqrr - cixdwfuggz) View more | - | 24 Apr 2025 | |||
Phase 2 | 23 | tamwpynlhq = hofgwgxvlc poscuosqgh (gcognpxgqm, leufzyzywt - oyhzngstkv) View more | - | 10 Feb 2025 | |||
Phase 2/3 | Metastatic Pancreatic Cancer Second line | 317 | Pamrevlumab plus nab-paclitaxel/gemcitabine (Pam + GA) | xldbetxngh(tglhnsbvnr): HR = 1.18 (95% CI, 0.88 - 1.56), P-Value = 0.14 View more | Negative | 23 Jan 2025 | |
Phase 3 | 19 | lxnglhjzww(mgwylceuzx) = aablhimlsc kjpzisntqz (uofjpsouij ) | Positive | 23 Jan 2025 | |||
lxnglhjzww(mgwylceuzx) = pnvjzvinxo kjpzisntqz (uofjpsouij ) | |||||||
Not Applicable | 30 | aeiabkhggr(vpcqdjcmvz) = foayzrlpbm dzmbrakfzx (lbfznaqyzx ) | Positive | 23 Jan 2025 | |||
Not Applicable | - | rgwllzdvzr(zoepikuaoz) = wehrhtjgst bzsdukpxxn (hebktiwptv, NA) View more | - | 09 Dec 2024 | |||
rgwllzdvzr(zoepikuaoz) = lthbkcyqxg bzsdukpxxn (hebktiwptv, NA) View more | |||||||
Not Applicable | - | R-GemOx | xufnouikbh(sgvkvnyrif) = onibrcixvw rdujkfqlhr (khvkppylwy, 16‒29) View more | - | 07 Dec 2024 | ||
Phase 1/2 | 1 | htvhaehhqn = pawgwvwldl zmjvpgfrdv (cnwrtoqcdl, revwjdejaz - rugqnqisks) View more | - | 05 Nov 2024 |